According to National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines, the detection of RAS and BRAF mutations is routinely carried out in tumor tissue from either biopsies or resected specimens of the primary tumor or of a metastatic lesion [13]. The gene discussed is BRAF; the disease is neoplasm.